Cartography CEO Kevin Parker, PhD sat down with Sarah Jones of Pear VC for the latest episode of Pear Biotech Bench to Business. Check it out to hear the latest on Cartography and insights on building a discovery pipeline based on new #cancer targets: https://bit.ly/3yeJ5DN
Cartography Biosciences’ Post
More Relevant Posts
-
🔬 GenomeWeb Interviews Novelna CEO on our MCED Test for Cancer Screening ✨ Featured on GenomeWeb, January 12, 2024 ✨ In a recent interview with GenomeWeb, our CEO, Ashkan Afshin, MD ScD, spoke about Novelna's innovative approach to cancer diagnostics. He highlighted our team's vision for developing a more affordable and sensitive multi-cancer early detection (MCED) test. Departing from DNA-based or multiomics methods, Novelna's approach focuses on using low-abundance proteins. This strategy is designed to enhance the accuracy of cancer screening while reducing costs, thereby making it more accessible, especially for asymptomatic individuals. Our initial proof of concept study, led by Bogdan Budnik from Harvard's Wyss Institute, has been published in BMJ Oncology. This research introduces two sex-specific panels for cancer detection, demonstrating promising results in the early detection of cancer. In his interview, Afshin elaborated on the challenges and immense potential of proteomics in cancer screening. This development is an important step toward enhancing technology and improving the accessibility of advanced healthcare. 🔗 Read the full article on GenomeWeb here: https://lnkd.in/gBxvmfeX #Novelna #DemocratizingDiagnostics #Proteomics #Diagnostics #CancerScreening #LiquidBiopsy #EarlyDetection #BMJOncology
To view or add a comment, sign in
-
Latest DON Monte Carlo news. Proud to announce that Telexos and Dr. Erhard Fernholz has joined DON Monte Carlo. We will be assisting them with their current funding round. Telexos develops products for the clinical cancer research market and for the personalized cancer diagnostics market. Focus of the developments is the detection and analysis of rare cells in blood, in particular circulating tumor cells (CTCs) and rare immune cells. Telexos started its laboratory in mid 2019. Circulating tumor cells (CTCs) can be detected in all solid tumors and are shed into the blood stream early on. CTCs have the advantage that the information (protein, RNA, DNA) of the different CTC-phenotypes are not mixed with others but are contained. Therefore, changes within the mixture of phenotypes during therapy can be easier detected. Since CTCs can be rare (e.g. 1 CTC in 10 billion blood cells) and quite heterogenous (reflecting the significant heterogeneity of the cells within a tumor of the same patient), it is mandatory to capture and analyze all available CTCs in a given blood sample. If not, important information in respect to determining the best available therapy and monitoring (and possibly adapting) the therapy in a personalized manner may be missed. We are always seeking new Biotech and Medtech funding opportunities for our network. Please submit you opportunity via this link - https://lnkd.in/dcvSMynH #biotech #opportunity #funding #oncology
To view or add a comment, sign in
-
Accelerating Early Cancer Detection with Advanced Proteomics and Multiplex Technology! In the relentless pursuit of advancing cancer research, scientists have discovered groundbreaking biomarkers that offer crucial insights into potential cancer or tumor growth. However, unlocking the full potential of these biomarkers required a powerful tool that could detect multiple biomarkers simultaneously. #xMAP's cutting-edge multiplex technology is a game-changer for researchers seeking unparalleled speed and efficiency in their work. With xMAP's reliable capabilities, scientists can now accelerate their investigations, enabling them to dive deeper into early-stage cancer research than ever before. To understand the profound impact of proteomics-based approaches and xMAP's contribution to early cancer detection, we invite you to explore our new white paper with Bio-Techne titled "The Role of Proteomics in Early Cancer Detection: A Look at Six Core Benefits." This insightful resource is now available for you to download and delve into the transformative potential of proteomics in the fight against cancer. Join us in the quest to push the boundaries of cancer research and detection. Together, we can make a difference. https://hubs.li/Q0221vcv0 #proteomics #cancerresearch #xMAP #biomarkers #multiplex #earlydetection #researchinnovation #bioinformatics #oncologyresearch #cancertreatment #scientists #medicalresearch #linkedinsights #sciencecommunity
To view or add a comment, sign in
-
Discover the future of Cancer treatment through Oncoimmunovaccinomics. 🧬 A study by Dr. Taruna Ikrar and his colleague Dr. Dito Anurogo explores the field of Oncoimmunovaccinomics, combining cancer immunotherapy and vaccinology to harness the immune system in the fight against cancer. Key highlights: ✔️ Personalized cancer vaccines ✔️ Breakthroughs in cancer immunotherapy classifications ✔️ The critical role of the tumor microenvironment ✔️ Nanotechnology's impact on immunotherapy We can see how this holistic approach harnesses the immune system's power, offering hope for more targeted, efficient, and less invasive cancer treatments. For a deeper dive into the molecular basis, therapeutic strategies, and visionary minds behind this transformative research, read Professor Ikrar’s full paper via the link in the first comment. #Cancer #Research #Immunotherapy #PersonalizedMedicine #Nanotechnology #Medicine
To view or add a comment, sign in
-
CAR T-cell Therapy Shows Exceptional Results Against Cutaneous and Rare Melanomas Exciting breakthrough! UCLA Health's Jonsson Comprehensive Cancer Center scientists have unveiled a cutting-edge CAR T-cell therapy targeting melanoma. The new approach, detailed in a Nature Communications article published on 9 February, harnesses TYRP1, a protein prevalent in melanoma cells, addressing the challenge of limited tumour targets. Preclinical tests in mice demonstrated impressive efficacy without severe side effects. Cristina Puig-Saus, Ph.D., highlights the therapy's potential against challenging melanoma types, urging clinical trials. This research marks a significant stride in personalised cancer treatment. Stay tuned as the team gears up for human trials, presenting a promising frontier in the battle against cancer. #CancerResearch #Innovation #CAR_T_CellTherapy #cancerimmunotherapy #immunooncology
To view or add a comment, sign in
-
Director of Learning and Development in the Life Sciences | Medical Affairs, Commercial | Technical Training | Soft Skills Training | Strategy | Leadership | Management
Join Dr. Mullin of the Roswell Park Comprehensive Cancer Center and Dr. Bao of the UPMC Hillman Cancer Center as they discuss AI's role in the real-time monitoring of patients receiving immunotherapy for immune-related adverse events (irAE). If you attend the free webinar, you’ll learn about: 1 - the current application of AI in irAE monitoring and detection. 2 - future applications of these technologies across the field. This webinar is the first of the 2024 SITC-NCI Computational Immuno-oncology Webinar Series, which focuses on the application of AI in immuno-oncology. https://buff.ly/3UoI0Sr #webinar #training #adverseevents #oncology #medicalaffairs #medaff #oncology
Real-Time AI Monitoring & Early Detection of Immune-Related Adverse Events | CBIIT
datascience.cancer.gov
To view or add a comment, sign in
-
Are you attending this year's American Association for Cancer Research annual meeting in San Diego? Our friends Epigene Labs are attending and presenting two posters on the use of AI to improve cancer treatments. If you're there, I recommend you reach out to founder and CEO Akpeli Nordor to get more insight on Epigene's work. #aacr #aacr24 #precisiononcology
Epigene Labs is thrilled to announce we will be presenting two posters at this year’s American Association for Cancer Research (#AACR) meeting in San Diego, April 5-10. The posters showcase our AI-powered framework for identifying and curating ‘omic datasets at scale, and their successful use for antigen target discovery across various cancer types. Abdelkader Behdenna Camille Marijon Julien Haziza Léa Meunier Akpeli Nordor from the Epigene team will be present on-site to discuss our findings. Our mission at Epigene Labs is to revolutionize oncology R&D with omic data and AI. The AACR meeting provides a space for researchers, academics and industry leaders, to collaborate and discuss advancements in precision oncology. We're honored to contribute our insights and innovative approaches to the future of cancer treatment at this event. If you're attending, we invite you to visit our posters and learn more about Epigene Labs and our work to make a meaningful impact in the fight against cancer. https://lnkd.in/g6P3g2CD #AACR24 #Cancer #Research #AI #Biotech #Innovation
To view or add a comment, sign in
-
This week at the ACCR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, we will present two posters highlighting preclinical data from our programs targeting RAS & RAF mutant tumors through deep cyclic inhibition of the #MAPKpathway. We look forward to joining academics, scientists, and industry colleagues from across the globe to discuss innovations in targeted therapeutics and continued clinical progress in cancer treatments. Find details about our presence at #Targets23: https://lnkd.in/eXxPiTiX American Association for Cancer Research National Cancer Institute (NCI) EORTC - European Organisation for Research and Treatment of Cancer #RASMutations #UniversalRAS #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #TargetedOncology #MetastaticCancer #AdvancedCancer
To view or add a comment, sign in
-
Principal Scientist | Immuno-oncology | Cancer Vaccines and Immunotherapy | Drug Discovery | Project Leader | R&D
CAR T-cell Therapy Shows Exceptional Results Against Cutaneous and Rare Melanomas Exciting breakthrough! UCLA Health's Jonsson Comprehensive Cancer Center scientists have unveiled a cutting-edge CAR T-cell therapy targeting melanoma. The new approach, detailed in a Nature Communications article published on 9 February, harnesses TYRP1, a protein prevalent in melanoma cells, addressing the challenge of limited tumour targets. Preclinical tests in mice demonstrated impressive efficacy without severe side effects. Cristina Puig-Saus, Ph.D., highlights the therapy's potential against challenging melanoma types, urging clinical trials. This research marks a significant stride in personalised cancer treatment. Stay tuned as the team gears up for human trials, presenting a promising frontier in the battle against cancer. #CancerResearch #Innovation #CAR_T_CellTherapy #cancerimmunotherapy #immunooncology
To view or add a comment, sign in
-
Just a week to go until our Cancer Tech Demo Day! On Thursday 12th October, you are invited to meet six outstanding teams from our Cancer Tech Accelerator 2023 cohort. Sentinal 4D – Sentinal 4D utilise 3D biology, microscopy and AI to link cell form to function and predict clinical success of novel therapeutics. Matt De Vries Chris Bakal myHT – myHT are tackling the challenges facing breast cancer survivors with an app that performs similarly to face-to-face psychological interventions. Lyndsay Hughes Upstream Genomics- Upstream Genomics is aiming to develop an improved approach to monitoring cancer patients. Richard Mair Wild Imaging – Wild Imaging are developing novel technologies for digital pathology and patient stratification. Maria Giovanna Lizio Generegualtion – Generegulation is developing a new generation of liquid biopsy techniques suited for early cancer detection and monitoring patient response to treatment. Vlad Teif Migration Biotherapeutics – Migration Biotherapeutics are developing a synthetic nerve that can be used to treat Glioblastoma Multiforme (GBM), the most common malignant brain tumour in adults. Peter Bannister Davide Danovi Kristin Polman These companies are developing innovative technologies to improve the prevention, diagnosis, treatment, and management of cancer. We are confident that their innovations will have a positive impact on the lives of cancer patients. Register now to save your place: https://lnkd.in/eq8WMbAs Nathan McNally Lotus Qi Lorraine Brown #Medtech #CTADemoDay #Healthinnovation
CTA Demo Day
eventbrite.co.uk
To view or add a comment, sign in
2,489 followers
Chemistry Ph.D. Candidate at Stanford University
2moThanks Kevin Parker for a great discussion!